Search for content, post, videos

Novo Nordisk does not intend to make a revised proposal for Ablynx

Novo Nordisk headquarters

The company notes the announcement of Sanofi’s agreed acquisition of Ablynx and confirms that it will not be making a revised proposal.

On 8 January, Novo Nordisk announced its proposal to acquire Ablynx for up to EUR 30.50 per share in cash, consisting of EUR 28.00 upfront and EUR 2.50 in Contingent Value Rights.

Novo Nordisk looks forward to continuing its productive research collaboration with Ablynx, they state in a press release.